3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Gastrointestinal
1
Conditions
Triple Negative Breast Neoplasms
4
Neoplasm Metastasis
4
Carcinoma, Non-Small-Cell Lung
4
Pancreatic Neoplasms
3
Head and Neck Neoplasms
3
Biliary Tract Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
2
Prostatic Neoplasms
2
Ovarian Neoplasms
2
Neoplasms
2
Esophageal Neoplasms
2
Colorectal Neoplasms
2
Carcinoma, Hepatocellular
2
Breast Neoplasms
2
Turcot syndrome
1
Solid Tumor, Adult
1
Rectal Neoplasms
1
Melanoma
1
Lung Neoplasms
1
Liver Neoplasms
1
Hyperthermia
1
Histiocytoma, Malignant Fibrous
1
Glioma
1
Esophageal Squamous Cell Carcinoma
1
Endometrial Neoplasms
1
Efficacy
1
Digestive System Neoplasms
1
Dermatofibrosarcoma
1
Colonic Neoplasms
1
Carcinoma, Transitional Cell
1
Interventions
pembrolizumab
16
Carboplatin
10
Paclitaxel
8
Nivolumab
7
Bevacizumab
6
Gemcitabine
4
Fulvestrant
4
Cisplatin
4
olaparib
3
lenvatinib
3
abemaciclib
3
PM 01183
3
Oxaliplatin
3
Leucovorin
3
Letrozole
3
Docetaxel
3
AZD5305
3
tisotumab vedotin
2
spartalizumab
2
sarilumab
2
sargramostim
2
sacituzumab govitecan
2
ribociclib
2
palbociclib
2
epacadostat
2
enzalutamide
2
dostarlimab
2
cemiplimab
2
anlotinib
2
X-Rays
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Endometrial Neoplasms
×
Immune Checkpoint Inhibitors
×
Clear all
NCT06710847
2026-02-02
SYLVER
GlaxoSmithKline
Phase 1/2
Active not recruiting
14 enrolled